[go: up one dir, main page]

RU2000102889A - APPLICATION OF KOLKHINOL DERIVATIVES AS A MEANS DAMAGING VESSELS - Google Patents

APPLICATION OF KOLKHINOL DERIVATIVES AS A MEANS DAMAGING VESSELS

Info

Publication number
RU2000102889A
RU2000102889A RU2000102889/14A RU2000102889A RU2000102889A RU 2000102889 A RU2000102889 A RU 2000102889A RU 2000102889/14 A RU2000102889/14 A RU 2000102889/14A RU 2000102889 A RU2000102889 A RU 2000102889A RU 2000102889 A RU2000102889 A RU 2000102889A
Authority
RU
Russia
Prior art keywords
alkyl
cycloalkyl
independently
use according
alkynyl
Prior art date
Application number
RU2000102889/14A
Other languages
Russian (ru)
Other versions
RU2232021C2 (en
Inventor
Грэм ДАУЭРТИ
Original Assignee
Энджиоджен Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714249.1A external-priority patent/GB9714249D0/en
Application filed by Энджиоджен Фармасьютикалз Лтд. filed Critical Энджиоджен Фармасьютикалз Лтд.
Publication of RU2000102889A publication Critical patent/RU2000102889A/en
Application granted granted Critical
Publication of RU2232021C2 publication Critical patent/RU2232021C2/en

Links

Claims (12)

l. Применение производных колхинола для получения композиций для лечения заболеваний, затрагивающих процесс образования сосудов, где производное колхинола имеет формулу
Figure 00000001

где R1, R2, R3 и R6 независимо представляют Н, необязательно замещенный алкил, циклоалкил, алкенил, алкинил, аралкил, алканоил, РО3Н2;
X представляет карбонил (СО), тиокарбонил (CS), метилен (СН2) или группу CHR4;
R4 представляет ОН, О-алкил или NR8R9;
R5 и R7 независимо представляют Н, алкил, галоген, гидрокси, алкокси, нитро- или аминогруппу;
R8 представляет Н, необязательно замещенный алкил, циклоалкил, алканоил, тиоалканоил, арил, гетероарил, арилкарбонил, гетероарилкарбонил, алкоксикарбонил, арилоксикарбонил, аминокарбонил, алкиламинокарбонил, диалкиламинокарбонил, ариламинокарбонил, алкилсульфонил, арилсульфонил, аминосульфонил, алкиламиносульфонил, диалкиламиносульфонил или ариламиносульфонил;
R9 представляет Н, алкил или циклоалкил;
и их фармацевтически приемлемых солей, сольватов и гидратов.
l. The use of colquinol derivatives to obtain compositions for the treatment of diseases affecting the process of vascular formation, where the colhinol derivative has the formula
Figure 00000001

where R 1 , R 2 , R 3 and R 6 independently represent H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, alkanoyl, PO 3 H 2 ;
X is carbonyl (CO), thiocarbonyl (CS), methylene (CH 2 ) or CHR 4 group;
R 4 is OH, O-alkyl or NR 8 R 9 ;
R 5 and R 7 are independently H, alkyl, halogen, hydroxy, alkoxy, nitro, or amino;
R 8 is an H 2 O 2
R 9 is H, alkyl or cycloalkyl;
and their pharmaceutically acceptable salts, solvates and hydrates.
2. Применение по п.1, где по меньшей мере один из R1, R2, R3 и R6 представляет РО3Н2.2. The use according to claim 1, wherein at least one of R 1 , R 2 , R 3 and R 6 is PO 3 H 2 . 3. Применение по п.2, где R6 представляет РО3Н2.3. The use according to claim 2, where R 6 is PO 3 H 2 . 4. Применение по любому из пп.1-3, где R1, R2 и R3представляют алкил.4. The use according to any one of claims 1 to 3, where R 1 , R 2 and R 3 are alkyl. 5. Применение по любому из пп.1-4, где R4 представляет ациламиногруппу.5. The use according to any one of claims 1 to 4 , where R 4 represents an acylamino group. 6. Применение по п.1, где R6 представляет РО3Н, R1, R2 и R3 представляют алкил, и R4 представляет ациламиногруппу.6. The use according to claim 1, wherein R 6 is PO 3 H, R 1 , R 2 and R 3 is alkyl, and R 4 represents an acylamino group. 7. Соединения формулы I, в которых по меньшей мере один из R1, R2, R3 и R6 представляет РО3Н2.7. Compounds of formula I in which at least one of R 1 , R 2, R 3 and R 6 is PO 3 H 2 . 8. Соединение по п.7, в котором R6 представляет РО3Н2.8. The compound according to claim 7, in which R 6 is PO 3 H 2 . 9. Соединение по п. 8, в которого R1, R2 и R3представляют алкил, R4 представляет ациламиногруппу.9. The compound according to claim 8, in which R 1 , R 2 and R 3 represent alkyl, R 4 represents an acylamino group. 10. Соединение по п.7 формулы
Figure 00000002

где R1, R2 и R3 независимо представляют H, необязательно замощенный алкил, циклоалкил, алкенил, алкинил, алканоил или РО3Н2;
R6 представляет РО3Н2;
R4 представляет Н или NR8R9;
R5 и R7 независимо представляют Н, алкил, галоген, алкокси-, нитро- или аминогруппу;
R8 представляет Н, необязательно замещенный алкил, циклоалкил, алканоил, тиоалканоил, арил, гетероарил, арилкарбонил, гетероарилкарбонил, алкоксикарбонил, арилоксикарбонил, аминокарбонил, алкиламинокарбонил, диaлкилaминoкapбoнил, ариламинокарбонил, алкилсульфонил, арилсульфонил, аминосульфонил, алкиламиносульфонил, диалкиламиносульфонил или ариламиносульфонил;
и R9 представляет Н, алкил или циклоалкил,
и его фармацевтически приемлемые соли, сольваты и гидраты.
10. The compound according to claim 7 of the formula
Figure 00000002

where R 1 , R 2 and R 3 independently represent H, optionally tiled alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl or PO 3 H 2 ;
R 6 is PO 3 H 2 ;
R 4 is H or NR 8 R 9 ;
R 5 and R 7 are independently H, alkyl, halogen, alkoxy, nitro or amino;
R 8 is a halogen free
and R 9 is H, alkyl or cycloalkyl,
and its pharmaceutically acceptable salts, solvates and hydrates.
11. Соединение формулы
Figure 00000003

где R1, R2 и R3 независимо представляют Н, необязательно замещенный алкил, циклоалкил, алкенил, алкинил, алканоил или РО3Н2;
R6 представляет Н, необязательно замещенный алкил, циклоалкил, алкенил, алкинил или РО3Н2;
R4 представляет Н или NR8R9;
R5 и R7 независимо представляют Н, аклил, галоген, нитро- или аминогруппу;
R8 представляет Н, необязательно замещенный алкил, циклоалкил, алканоил, тиоалканоил, арил, гетероарил, арилкарбонил, гетероарилкарбонил, алкоксикарбонил, арилоксикарбонил, аминокарбонил, алкиламинокарбонил, диалкиламинокарбонил, ариламинокарбонил, алкил сульфонил, арилсульфонил, аминосульфонил, алкиламиносульфонил, диалкиламиносульфонил или ариламиносульфонил;
и R9 представляет Н, алкил или циклоалкил при условии, что когда R1, R2 и R3 все представляют метильные группы и R4представляет водород, ацетиламино-, ацетилметиламино-, амино, метиламино- или диметиламиногруппу, тогда R6 не является водородом, метилом, гидроксиэтилом или ацетоксиэтилом,
и его фармацевтически приемлемые соли, сольваты и гидраты.
11. The compound of the formula
Figure 00000003

where R 1 , R 2 and R 3 independently represent H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl or PO 3 H 2 ;
R 6 is H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl or PO 3 H 2 ;
R 4 is H or NR 8 R 9 ;
R 5 and R 7 are independently H, alkyl, halogen, nitro or amino;
R 8 is an option for an ally
and R 9 is H, alkyl or cycloalkyl, provided that when R 1 , R 2 and R 3 are all methyl groups and R 4 is hydrogen, acetylamino, acetylmethylamino, amino, methylamino or dimethylamino, then R 6 is not hydrogen, stands, hydroxyethyl or acetoxyethyl,
and its pharmaceutically acceptable salts, solvates and hydrates.
12. Соединение по п. 11, в котором R1, R2 и R3представляют алкил и R4 представляет ациламиногруппу.12. The compound according to claim 11, in which R 1 , R 2 and R 3 represent alkyl and R 4 represents acylamino group.
RU2000102889/15A 1997-07-08 1998-07-06 Application of colchinol derivatives as agents impairing vessels RU2232021C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9714249.1 1997-07-08
GBGB9714249.1A GB9714249D0 (en) 1997-07-08 1997-07-08 Vascular damaging agents

Publications (2)

Publication Number Publication Date
RU2000102889A true RU2000102889A (en) 2001-10-27
RU2232021C2 RU2232021C2 (en) 2004-07-10

Family

ID=10815450

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000102889/15A RU2232021C2 (en) 1997-07-08 1998-07-06 Application of colchinol derivatives as agents impairing vessels

Country Status (24)

Country Link
US (1) US6423753B1 (en)
EP (1) EP1001785B1 (en)
JP (1) JP3455549B2 (en)
KR (1) KR100655808B1 (en)
CN (1) CN1181825C (en)
AT (1) ATE334684T1 (en)
AU (1) AU741213B2 (en)
BR (1) BR9810681A (en)
CA (1) CA2292549C (en)
CZ (1) CZ296018B6 (en)
DE (1) DE69835434T2 (en)
ES (1) ES2270524T3 (en)
GB (1) GB9714249D0 (en)
HU (1) HUP0002493A3 (en)
ID (1) ID25483A (en)
IL (1) IL133899A0 (en)
NO (2) NO321621B1 (en)
NZ (1) NZ501341A (en)
PL (1) PL337926A1 (en)
RU (1) RU2232021C2 (en)
SK (1) SK132000A3 (en)
TR (1) TR199903149T2 (en)
UA (1) UA72731C2 (en)
WO (1) WO1999002166A1 (en)

Families Citing this family (376)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900334D0 (en) * 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
MXPA01008182A (en) 1999-02-10 2003-08-20 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors.
SE9903544D0 (en) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
RU2268729C2 (en) * 2000-03-31 2006-01-27 Энджиоджен Фармасьютикалз Лтд. Combined therapies using of angiogenesis damaging activity
CN1422157A (en) * 2000-03-31 2003-06-04 安吉奥金尼药品有限公司 Fractionated dose therapy utilizing vasodisruptive activity
EE200200565A (en) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Combination therapy with vascular adverse effects
EP1289952A1 (en) * 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
CA2411160A1 (en) * 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
MXPA02012903A (en) * 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors.
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0003828D0 (en) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1438281A4 (en) 2001-10-26 2006-04-26 Oxigene Inc FUNCTIONALIZED STYLENE DERIVATIVES AS IMPROVED MEDIUM-TERM MEDICAL DEVICES
US7268230B2 (en) 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
AU2003216558B2 (en) * 2002-04-16 2008-05-29 Astrazeneca Ab Combination therapy for the treatment of cancer
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
US7482355B2 (en) 2002-08-24 2009-01-27 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (en) * 2002-12-06 2006-10-27 Aventis Pharma Sa COLCHICINE DERIVATIVES, PREPARATION METHOD, PRODUCTS OBTAINED BY THIS PROCESS AND USE
PL221490B1 (en) 2002-12-24 2016-04-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
EP1601348A4 (en) 2003-02-28 2008-12-10 Oxigene Inc Compositions and methods with enhanced therapeutic activity
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (en) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
BRPI0411567A (en) * 2003-06-18 2006-08-01 Angiogene Pharm Ltd use of zd6126 or a pharmaceutically acceptable salt thereof and one of 5-fu, cpt-11, and 5-fu and cpt-11, pharmaceutical composition, kit, and methods for producing a vascular damage effect in an animal of warm blood and for the treatment of a cancer involving a solid tumor in a warm blooded animal
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
EP2251327B1 (en) 2003-11-19 2014-02-12 Array Biopharma, Inc. Heterocyclic inhibitors of mek
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
GB0329771D0 (en) * 2003-12-23 2004-01-28 Angiogene Pharm Ltd Chemical processes & intermediates
WO2005066163A2 (en) 2004-01-05 2005-07-21 Astrazeneca Ab Thiophene derivatives as chk 1 inihibitors
SE0401657D0 (en) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
RS53145B (en) 2004-08-28 2014-06-30 Astrazeneca Ab. PIRIMIDINE SULFONAMIDE DERIVATIVES AS CHEMOKIN RECEPTOR MODULATORS
CN105085678B (en) 2004-12-21 2019-05-07 阿斯利康公司 Angiopoietin-2 antibody and its application
ES2555063T3 (en) 2005-02-04 2015-12-28 Astrazeneca Ab Pyrazolilaminopyridine derivatives useful as kinase inhibitors
EP2361905B1 (en) 2005-05-18 2013-03-06 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
WO2007011293A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
JPWO2007034917A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
JPWO2007034882A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
WO2007034881A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
JPWO2007034817A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
US20090099216A1 (en) 2005-09-22 2009-04-16 Astrazeneca Aktiebolag A Corporation Of Sweden Novel adenine compound
US7384935B2 (en) * 2005-09-27 2008-06-10 Thallion Pharmaceuticals, Inc. Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
RU2463302C2 (en) 2005-10-28 2012-10-10 Астразенека Аб 4-(3-aminopyrazole)pyrimidine applicable as tyrosine kinase inhibitors for treating malignant growth
CN101356171A (en) 2005-11-15 2009-01-28 阿雷生物药品公司 N4-phenyl-quinazolin-4-amine derivatives and related compounds as ERBBI type receptor tyrosine kinase inhibitors for the treatment of proliferative diseases
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
ES2385054T3 (en) 2005-12-13 2012-07-17 Medimmune Limited Specific binding proteins for insulin-like growth factors and uses thereof
US20080293775A1 (en) 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CN101454284A (en) 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 Biaryl or aryl-heteroaryl substituted indoles
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
DE102006037478A1 (en) 2006-08-10 2008-02-14 Merck Patent Gmbh 2- (Heterocyclylbenzyl) -pyridazinone derivatives
NZ575672A (en) 2006-08-23 2011-10-28 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2008075005A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
CL2008000191A1 (en) 2007-01-25 2008-08-22 Astrazeneca Ab COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER.
JPWO2008114819A1 (en) 2007-03-20 2010-07-08 大日本住友製薬株式会社 New adenine compounds
PE20081887A1 (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
DE102007025717A1 (en) 2007-06-01 2008-12-11 Merck Patent Gmbh Aryl ether pyridazinone derivatives
DE102007025718A1 (en) 2007-06-01 2008-12-04 Merck Patent Gmbh pyridazinone derivatives
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
UA100983C2 (en) 2007-07-05 2013-02-25 Астразенека Аб Biphenyloxypropanoic acid as crth2 modulator and intermediates
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007038957A1 (en) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-thioxo-pyridazine derivatives
DE102007041115A1 (en) 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
WO2009044200A1 (en) 2007-10-04 2009-04-09 Astrazeneca Ab Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity
JP4705695B2 (en) 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ Pyrrolo [2,3-D] pyrimidine derivatives as protein kinase B inhibitors
US20090192098A1 (en) 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2245064B1 (en) 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
ES2394547T3 (en) 2008-02-06 2013-02-01 Astrazeneca Ab Compounds
EP2254889B1 (en) 2008-02-28 2012-12-19 Merck Patent GmbH Protein kinase inhibitors and use thereof
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
AU2009252938B2 (en) 2008-05-27 2012-04-26 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
DE102008025750A1 (en) 2008-05-29 2009-12-03 Merck Patent Gmbh Dihydropyrazolderivate
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008029734A1 (en) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidine derivatives
TWI461423B (en) 2008-07-02 2014-11-21 Astrazeneca Ab Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
DE102008037790A1 (en) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclic triazole derivatives
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
DE102008052943A1 (en) 2008-10-23 2010-04-29 Merck Patent Gmbh azaindole derivatives
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
CA2746652C (en) 2008-12-11 2018-03-06 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US20100152197A1 (en) 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
AU2009333653B2 (en) 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
ES2603208T3 (en) 2008-12-18 2017-02-24 Merck Patent Gmbh Tricyclic azaindoles
DE102008063667A1 (en) 2008-12-18 2010-07-01 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
DE102008062825A1 (en) 2008-12-23 2010-06-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008062826A1 (en) 2008-12-23 2010-07-01 Merck Patent Gmbh pyridazinone derivatives
DE102009003954A1 (en) 2009-01-07 2010-07-08 Merck Patent Gmbh pyridazinone derivatives
DE102009003975A1 (en) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
DE102009004061A1 (en) 2009-01-08 2010-07-15 Merck Patent Gmbh pyridazinone derivatives
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CN102388048B (en) 2009-02-10 2014-07-30 阿斯利康(瑞典)有限公司 Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
ES2529205T3 (en) 2009-03-13 2015-02-17 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
UY32520A (en) 2009-04-03 2010-10-29 Astrazeneca Ab COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
US20120172385A1 (en) 2009-09-11 2012-07-05 Richard John Harrison Ortho substituted pyrimidine compounds as jak inhibitors
DE102009043260A1 (en) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolone derivatives
RU2012116877A (en) 2009-10-02 2013-11-10 Астразенека Аб COMPOUNDS OF 2-PYRIDONE USED AS NEUTROPHIL ELASTASE INHIBITORS
DE102009049679A1 (en) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
MX2012004020A (en) 2009-10-20 2012-05-08 Cellzome Ltd Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors.
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
AU2010322478B2 (en) 2009-11-18 2013-11-14 Glaxosmithkline Intellectual Property (No. 3) Limited Benzoimidazole compounds and uses thereof
CA2778714C (en) 2009-11-24 2018-02-27 Medimmune Limited Targeted binding agents against b7-h1
WO2011068233A1 (en) 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
DE102009058280A1 (en) 2009-12-14 2011-06-16 Merck Patent Gmbh thiazole
BR112012014164A2 (en) 2009-12-14 2016-05-17 Merck Patent Gmbh sphingosine kinase inhibitors
CN102639513A (en) 2009-12-17 2012-08-15 默克专利有限公司 Sphingosine kinase inhibitors
AU2011206864B2 (en) 2010-01-15 2013-12-19 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
WO2011089416A1 (en) 2010-01-19 2011-07-28 Astrazeneca Ab Pyrazine derivatives
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
US20130131043A1 (en) 2010-04-30 2013-05-23 Richard John Harrison Pyrazole compounds as jak inhibitors
US20130059916A1 (en) 2010-05-26 2013-03-07 Stephane Rocchi Biguanide compounds and its use for treating cancer
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl compounds for use as ATR inhibitors
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
TWI535712B (en) 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
DE102010034699A1 (en) 2010-08-18 2012-02-23 Merck Patent Gmbh pyrimidine derivatives
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
DE102010048800A1 (en) 2010-10-20 2012-05-10 Merck Patent Gmbh quinoxaline
DE102010049595A1 (en) 2010-10-26 2012-04-26 Merck Patent Gmbh quinazoline derivatives
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
JP2013542916A (en) 2010-11-19 2013-11-28 大日本住友製薬株式会社 Cyclic amide compounds and their use in the treatment of diseases
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
ES2575688T3 (en) 2010-12-16 2016-06-30 Sumitomo Dainippon Pharma Co., Ltd. Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
RU2013133846A (en) 2010-12-20 2015-01-27 Медиммьюн Лимитед ANTIBODIES AGAINST IL-18 AND THEIR APPLICATION
WO2012103810A1 (en) 2011-02-02 2012-08-09 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
EP2694511A1 (en) 2011-04-04 2014-02-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
MX353334B (en) 2011-07-12 2018-01-09 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator.
JP5427321B2 (en) 2011-07-27 2014-02-26 アストラゼネカ アクチボラグ 2- (2,4,5-substituted-anilino) pyrimidine compounds
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
DE102011111400A1 (en) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclic heteroaromatic compounds
CN107245056A (en) 2011-08-26 2017-10-13 润新生物公司 Chemical entities, composition and method
WO2013033250A1 (en) 2011-09-01 2013-03-07 Xiangping Qian Certain chemical entities, compositions, and methods
US9518029B2 (en) 2011-09-14 2016-12-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2012311504B2 (en) 2011-09-20 2016-03-24 Cellzome Limited Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors
BR112014006743A8 (en) 2011-09-21 2018-01-09 Cellzome Ltd compound, use of a compound, and method for treating, controlling, retarding or preventing one or more conditions
EP2757885B1 (en) 2011-09-21 2017-03-15 Neupharma, Inc. Certain chemical entites, compositions, and methods
EP2760458B1 (en) 2011-09-29 2017-06-14 The University of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
WO2013049701A1 (en) 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9242993B2 (en) 2011-10-07 2016-01-26 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
CN104169272A (en) 2011-12-23 2014-11-26 赛尔佐姆有限公司 Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US9670180B2 (en) 2012-01-25 2017-06-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2807161B1 (en) 2012-01-28 2017-10-04 Merck Patent GmbH Triazolo[4,5-d]pyrimidine derivatives
RS55388B1 (en) 2012-02-09 2017-03-31 Merck Patent Gmbh FURO [3, 2 - B] PIRIDIN DERIVATIVES AS TBK1 AND IKK INHIBITORS
EP2812323B1 (en) 2012-02-09 2016-04-06 Merck Patent GmbH Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
EP2817310B1 (en) 2012-02-21 2018-03-21 Merck Patent GmbH 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
CA2865040C (en) 2012-02-21 2020-07-14 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
ES2606638T3 (en) 2012-02-21 2017-03-24 Merck Patent Gmbh Furopyridine derivatives
CA2866450C (en) 2012-03-07 2020-02-18 Merck Patent Gmbh Triazolopyrazine derivatives
WO2013144532A1 (en) 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
KR101674784B1 (en) 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 Bispecific antibodies against human tweak and human il17 and uses thereof
EP2852285B1 (en) 2012-04-29 2018-08-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by a heterocyclic amine for use in the treatment of cancer
AU2013257018B2 (en) 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
WO2014015934A1 (en) 2012-07-24 2014-01-30 Merck Patent Gmbh Hydroxystatin derivatives for treatment of arthrosis
CA2881279C (en) 2012-08-07 2020-07-07 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
AU2013301870B2 (en) 2012-08-08 2017-04-27 Merck Patent Gmbh (Aza-)isoquinolinone derivatives
US20160009686A1 (en) 2012-08-17 2016-01-14 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
CN102898330B (en) * 2012-09-03 2015-02-25 浙江大学 Colchicine Derivatives
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9388142B2 (en) 2012-09-26 2016-07-12 Merck Patent Gmbh Quinazolinone derivatives as PARP inhibitors
EP2911692B1 (en) 2012-10-26 2019-08-21 The University of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
JP6304776B2 (en) 2012-11-05 2018-04-04 ジーエムディーエックス カンパニー プロプライエタリー リミテッド Method for determining the cause of somatic mutagenesis
WO2014075077A1 (en) 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2014075754A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN105246888B (en) 2013-01-31 2017-09-05 尼奥迈德研究所 Imidazopyridine compounds and uses thereof
CA2902080A1 (en) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydroquinazoline derivatives and the use thereof as cathepsin d inhibitors
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
CN105142648A (en) 2013-03-15 2015-12-09 玛格塞蒂克斯公司 Magnesium compositions for cancer and uses thereof
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP3004073A1 (en) 2013-06-07 2016-04-13 Université catholique de Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
WO2014205511A1 (en) 2013-06-25 2014-12-31 University Of Canberra Methods and compositions for modulating cancer stem cells
CN111285813A (en) 2013-08-23 2020-06-16 润新生物公司 Chemical entities, compositions and methods
ES2851724T3 (en) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Stem cell modulation
EP3052660A4 (en) 2013-10-01 2017-04-26 Queensland University Of Technology Kits and methods for diagnosis, screening, treatment and disease monitoring
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
EP3185858A4 (en) 2014-08-25 2017-12-27 University of Canberra Compositions for modulating cancer stem cells and uses therefor
WO2016077881A1 (en) 2014-11-17 2016-05-26 The University Of Queensland Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
MA41179A (en) 2014-12-19 2017-10-24 Cancer Research Tech Ltd PARG INHIBITOR COMPOUNDS
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CN107613769A (en) 2015-02-17 2018-01-19 润新生物公司 Certain chemical entities, compositions and methods
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
EP3957637B1 (en) 2015-08-04 2023-06-28 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
JP6850294B2 (en) 2015-08-26 2021-03-31 ジーエムディーエックス カンパニー プロプライエタリー リミテッド How to Detect Cancer Recurrence
KR20180095694A (en) 2015-12-23 2018-08-27 퀸스랜드 유니버시티 오브 테크놀로지 Nucleic acid oligomers and uses thereof
CN116082457A (en) 2016-02-01 2023-05-09 堪培拉大学 Protein compounds and uses thereof
CA3014674C (en) 2016-02-15 2024-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods comprising fixed intermittent dosing of cediranib
HUE060082T2 (en) 2016-04-15 2023-01-28 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
HUE059242T2 (en) 2016-07-29 2022-11-28 Rapt Therapeutics Inc Azetidine derivatives as chemokine receptor modulators and their use
CA3033370A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
ES2845048T3 (en) 2016-09-22 2021-07-23 Cancer Research Tech Ltd Preparation and uses of pyrimidinone derivatives
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
BR112019011284A2 (en) 2016-12-05 2019-10-22 Apros Therapeutics, Inc compound, pharmaceutical composition, methods of treating a condition, hbv and cancer, and, use of a compound.
JP7113528B2 (en) 2017-02-01 2022-08-05 オーセントラ セラピュティクス ピーティーワイ エルティーディー N-Cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine derivatives as therapeutic agents
WO2018162625A1 (en) 2017-03-09 2018-09-13 Truly Translational Sweden Ab Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN108864079B (en) 2017-05-15 2021-04-09 深圳福沃药业有限公司 Triazine compound and pharmaceutically acceptable salt thereof
EP3630749B9 (en) 2017-05-26 2024-05-29 Cancer Research Technology Limited 2-quinolone derived inhibitors of bcl6
KR102828518B1 (en) 2017-05-26 2025-07-04 캔써 리서치 테크놀로지 리미티드 Benzimidazolone derived inhibitors of bcl6
WO2018220101A1 (en) 2017-05-31 2018-12-06 Truly Translational Sweden Ab A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
AU2017422200B2 (en) 2017-07-05 2022-11-24 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates
SG11202000823WA (en) 2017-08-01 2020-02-27 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
WO2019034890A1 (en) 2017-08-18 2019-02-21 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
CA3073343A1 (en) 2017-08-21 2019-02-28 Merck Patent Gmbh Quinoxaline derivatives as adenosine receptor antagonists
IL272637B2 (en) 2017-08-21 2024-03-01 Merck Patent Gmbh Benzimidazole derivatives, their preparation and medicaments containing them
TWI702205B (en) 2017-10-06 2020-08-21 俄羅斯聯邦商拜奧卡德聯合股份公司 Epidermal growth factor receptor inhibitors
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
KR20200104291A (en) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. Anticancer drugs
EP3488868B1 (en) 2017-11-23 2023-09-13 medac Gesellschaft für klinische Spezialpräparate mbH Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
EP3489222A1 (en) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazine salts, production processes and uses
JP7406808B2 (en) 2018-01-15 2023-12-28 オーセントラ セラピュティクス ピーティーワイ エルティーディー 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
RU2020128176A (en) 2018-01-26 2022-03-02 Рапт Терапьютикс, Инк. CHEMOKINE RECEPTOR MODULATORS AND THEIR APPLICATIONS
CA3090528A1 (en) 2018-02-08 2019-08-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
KR20250105504A (en) 2018-04-13 2025-07-08 캔써 리서치 테크놀로지 리미티드 Bcl6 inhibitors
JP7427655B2 (en) 2018-04-27 2024-02-05 スプルース バイオサイエンシーズ,インク. Methods for Treating Testicular Adrenal Residual Tumors and Ovarian Adrenal Residual Tumors
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
CN112513031A (en) 2018-06-04 2021-03-16 阿普罗斯治疗公司 Acid group containing pyrimidine compounds useful for the treatment of diseases associated with the modulation of TLR7
EP3802544A1 (en) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
FI4360713T3 (en) 2018-09-18 2024-12-27 Hoffmann La Roche Quinazoline derivatives as antitumor agents
WO2020068600A1 (en) 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
ES2960883T3 (en) 2018-10-25 2024-03-07 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
JP7551607B2 (en) 2018-10-25 2024-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 5-Azaindazole Derivatives as Adenosine Receptor Antagonists
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
CN114729354A (en) 2018-12-25 2022-07-08 中国医学科学院基础医学研究所 Small RNA drugs for prevention and treatment of inflammatory related diseases and their combinations
AR117844A1 (en) 2019-01-22 2021-09-01 Merck Patent Gmbh THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR
JP7578602B2 (en) 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー3)、リミテッド Treatment with P2X3 modulators
US11033547B2 (en) 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
CA3130727A1 (en) 2019-03-28 2020-10-01 Amplia Therapeutics Limited A salt and crystal form of a fak inhibitor
CN111747950B (en) 2019-03-29 2024-01-23 深圳福沃药业有限公司 Pyrimidine derivatives for the treatment of cancer
MX2021011810A (en) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer.
EP3946618A1 (en) 2019-04-05 2022-02-09 Storm Therapeutics Ltd Mettl3 inhibitory compounds
CA3127475A1 (en) 2019-04-08 2020-10-15 Merck Patent Gmbh Pyrimidinone derivatives as shp2 antagonists
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
CN114728910B (en) 2019-08-31 2024-05-14 上海奕拓医药科技有限责任公司 Pyrazole derivatives for FGFR inhibitors and preparation methods thereof
TWI873187B (en) 2019-09-20 2025-02-21 美商愛德亞生物科學公司 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
US20230183197A1 (en) 2020-06-01 2023-06-15 Neophore Limited Inhibitors of mlh1 and/or pms2 for cancer treatment
GB202012482D0 (en) 2020-08-11 2020-09-23 Univ Of Huddersfield Novel compounds and therapeutic uses thereof
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
CA3218697A1 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
JP2024519054A (en) 2021-05-17 2024-05-08 エイチケイ イノ.エヌ コーポレーション BENZAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF CANCER - Patent application
CN117999101A (en) 2021-05-25 2024-05-07 默克专利股份公司 Fc antigen-binding fragment-drug conjugate targeting EGFR
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
IT202100023357A1 (en) 2021-09-09 2023-03-09 Cheirontech S R L Peptides with anti-angiogenic activity
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
GB202117224D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Inhibitor compounds
GB202117225D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
CN119421877A (en) 2022-01-10 2025-02-11 默克专利股份公司 Substituted heterocyclic compounds as HSET inhibitors
GB202202006D0 (en) 2022-02-15 2022-03-30 Chancellor Masters And Scholars Of The Univ Of Oxford Anti-cancer treatment
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
WO2023196432A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
EP4522597A1 (en) 2022-05-11 2025-03-19 Cancer Research Technology Limited Ikk inhibitors
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
WO2024094963A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
WO2024094962A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
AR130957A1 (en) 2022-11-07 2025-02-05 Merck Patent Gmbh SUBSTITUTED BICYCLIC AND TRICYCLIC HSET INHIBITORS
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
GB202300881D0 (en) 2023-01-20 2023-03-08 Neophore Ltd Inhibitor compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
US12145945B2 (en) 2023-03-10 2024-11-19 Breakpoint Therapeutics Gmbh Compounds, compositions, and therapeutic uses thereof
EP4688159A1 (en) 2023-04-05 2026-02-11 FoRx Therapeutics AG Parg inhibitory compounds
GB202306601D0 (en) 2023-05-04 2023-06-21 Cancer Research Tech Ltd Inhibitor compounds
GB202307924D0 (en) 2023-05-26 2023-07-12 Neophore Ltd Inhibitor compounds
GB2631509A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
GB2631507A (en) 2023-07-04 2025-01-08 Univ Liverpool Compositions
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025056923A1 (en) 2023-09-15 2025-03-20 Cambridge Enterprise Limited Combination therapy
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
WO2025073870A1 (en) 2023-10-03 2025-04-10 Forx Therapeutics Ag Parg inhibitory compound
GB202315149D0 (en) 2023-10-03 2023-11-15 Celleron Therapeutics Ltd Combination therapy
GB202316595D0 (en) 2023-10-30 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
GB202316683D0 (en) 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
GB202317368D0 (en) 2023-11-13 2023-12-27 Breakpoint Therapeutics Gmbh Novel compounds, compositions and therapeutic uses thereof
WO2025104443A1 (en) 2023-11-14 2025-05-22 Storm Therapeutics Ltd Inhibitory compounds
WO2025114480A1 (en) 2023-11-28 2025-06-05 Forx Therapeutics Ag Wrn inhibitory compounds
WO2025136811A1 (en) 2023-12-18 2025-06-26 Ideaya Biosciences, Inc. Chemical compounds and uses thereof
GB202319863D0 (en) 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Movel compounds, compositions and therapeutics uses thereof
GB202319864D0 (en) 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Novel compounds, compositions and therapeutic uses thereof
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025191176A1 (en) 2024-03-14 2025-09-18 Forx Therapeutics Ag Wrn inhibitory compounds
NL2037411B1 (en) 2024-04-08 2025-10-31 Univ Leiden Protac compounds
GB202407738D0 (en) 2024-05-31 2024-07-17 Storm Therapeutics Ltd Inhibitory compounds
WO2025262192A1 (en) 2024-06-21 2025-12-26 Breakpoint Therapeutics Gmbh Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
WO2026003380A1 (en) 2024-06-28 2026-01-02 Forx Therapeutics Ag Wrn inhibitory compounds
WO2026022150A1 (en) 2024-07-22 2026-01-29 Forx Therapeutics Ag Parg inhibitory compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3442953A (en) * 1963-06-19 1969-05-06 Roussel Uclaf Novel 7-oxo-7-desacetylaminocolchicine compounds
IT1270124B (en) 1994-10-05 1997-04-28 Indena Spa COLCHICINE DERIVATIVES AND THEIR THERAPEUTIC USE
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
IT1276996B1 (en) 1995-06-27 1997-11-04 Indena Spa COLCHICINE DERIVATIVES, THEIR USE AND FORMULATIONS CONTAINING THEM
US5760092A (en) 1995-09-13 1998-06-02 Brandeis University Allocolchinones and uses thereof
IT1283110B1 (en) * 1996-06-07 1998-04-07 Indena Spa COLCHYCINE SKELETON COMPOUNDS, THEIR USE AS DRUGS AND COMPOSITIONS THAT CONTAIN THEM
IT1291550B1 (en) * 1997-04-11 1999-01-11 Indena Spa DERIVATIVES OF COLCHICINE AND THIOCOLCHICINE WITH ANTI-INFLAMMATORY AND MYORELAXING ACTIVITIES
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
JP2002537262A (en) 1999-02-18 2002-11-05 オキシジェン,インコーポレイティド Compositions and methods for use in targeting vascular disruption

Similar Documents

Publication Publication Date Title
RU2000102889A (en) APPLICATION OF KOLKHINOL DERIVATIVES AS A MEANS DAMAGING VESSELS
EP2067784A3 (en) 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
WO2003035668A3 (en) Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
CA2161542A1 (en) Novel 5-Pyrrolyl-2-Pyridylmethylsulfinyl Benzimidazole Derivatives
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DE69221563D1 (en) Polyfluoroalkylthiopoly (ethylimidazolium) compounds, process for their preparation and their use as biocidal agents
ATE83773T1 (en) 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-SRS-A AGENT CONTAINING IT.
AU6652390A (en) Compositions and their use in lowering intraocular pressure
RU2003134629A (en) CEPHEMA COMPOUNDS
AR036176A1 (en) A PHENYL-ACETAMID-TIAZOL DERIVATIVE, A PROCEDURE FOR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A PRODUCT OR KIT THAT UNDERSTANDS THEM, AND A METHOD THAT USES SUCH DERIVATIVE
DE59208058D1 (en) New tetrazole derivatives, processes for their preparation and their use
DE69330601D1 (en) SEROTON INERGIC ERGOLIN DERIVATIVES
IL112432A0 (en) Fatty acid derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
DE3868013D1 (en) THIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
NZ504706A (en) Substituted isoquinoline derivatives and their use as anticonvulsants
DE59800034D1 (en) 11 beta-benzaldoxim-9 alpha, 10 alpha-epoxy-estr-4-ene derivatives, process for their preparation and pharmaceutical preparations containing these compounds
DE60020130D1 (en) PROCESS FOR THE PREPARATION OF 3-AMINO-GALLENSAUR DERIVATIVES
PL334088A1 (en) Novel derivatives of n-benzenesulphonyl-l-proline, methods of obtaining them and pharmaceutic agents
AU1076802A (en) Selective glucocorticoid receptor agonists
BR0112957A (en) Compound, method of treatment, use of a compound, and pharmaceutical composition
AR046212A1 (en) DERIVATIVES OF 2-PHENYLBENZOFURANE, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE3671016D1 (en) THIAZOLIDE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.